glp-1/glucagon dual receptor agonist Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are The dual glucose-dependent insulinotropic polypeptide

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a copper-binding tripeptide first isolated from human plasma, studied in preclinical models for its effects on gene expression, extracellular matrix remodeling, and oxidative-stress biology

Peptides are small chains of amino acids that help your body heal and repair itself

The chronic use of any of these medications has the potential to cause complications related to vitamin B12 deficiency, which includes impaired DNA synthesis, impaired cell division, hematopoiesis, hyperhomocysteinemia, and metabolism of odd-chain fatty acids that is necessary in preventing demyelination of nerves

Ethical sourcing and responsive, knowledgeable customer service

The effects of dual GLP-1/GIP receptor agonism on glucagon secretion: a review